KKR (KKR) announced a new platform established with investments from KKR and Hologic (HOLX). The new platform, named Maverix Medical, will be managed by Ajax Health under the leadership of Duke Rohlen. Maverix will develop and acquire innovative technologies and commercial operations within the lung cancer disease category. KKR and Ajax Health will contribute existing portfolio company Serpex Medical to the platform. Serpex Medical develops steerable technology that can target lung tissue for biopsy or delivery of therapy. KKR is investing in Maverix through its Health Care Strategic Growth strategy. Additional terms of the transaction were not disclosed.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KKR:
- KKR price target raised to $92 from $82 at Barclays
- KKR call volume above normal and directionally bullish
- BofA expects KKR and Apollo Global to be added to S&P 500 over next 6 months
- KKR to acquire remaining 37% of Global Atlantic for $2.7B in cash
- KKR acquires Potter Global Technologies, terms undisclosed
